Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

al insights into the potential utility of RIT in intermediate grade NHL, a subtype where CRs are infrequent with rituximab therapy," noted Jack W. Singer, M.D., Chief Medical Officer of CTI.

The study results are reported in the current issue of CANCER at http://www3.interscience.wiley.com/journal/104532863/issue

Study Details

Between February 2005 and June 2006 26 eligible patients with previously untreated, indolent, nonfollicular NHL (10 marginal zone, 8 lymphocytoplasmic, and 8 small lymphocytic) were treated using a novel regimen that consisted of 6 cycles of fludarabine/mitoxantrone (FM) chemotherapy followed 6 to 10 weeks later by yttrium-90(90Y) ibritumomab tiuxetan (Zevalin(R)). After chemotherapy the overall response rate was 80.5% and included 50% CR and 30.5% PR. Of the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The FM treatment was well-tolerated; there were no treatment-related deaths. Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. Only 1 patient developed febrile neutropenia. Following Zevalin administration grade 3-4 thrombocytopenia occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors concluded "In this study we established the feasibility, tolerability and efficacy of sequential treatement with 6 cycles of FM chemotherapy followed by 90Y ibritumomab tiuxetan as front line therapy for patients with untreated, indolent, nonfollicular NHL. To our knowledge the data repr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... -- Numotion is pleased to announce the appointment of Mark ... Mark is a 30-year retired veteran of GE where ... and was a GE Company Officer since 1999 and a ... running business units within GE Healthcare, with the most recent ... "We are delighted to welcome Mark to our Board," ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:9/3/2014)... CA (PRWEB) September 03, 2014 AttorneyOne.com, a ... the latest information from the FDA on Pedigree nutrition ... August 26, that 22 bags of Pedigree Adult Complete Nutrition ... the possible presence of a foreign material. The reason for ... fragments, which could have entered the packages during the production ...
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... September 03, 2014 Pwnie Express today ... cutting edge Pwn Plug, the R3, an inconspicuous pentesting ... of use at remote locations at a fraction of ... Pwnie Express is the only company to assess wired ... Plug R3 is a next-generation penetration testing device in ...
(Date:9/3/2014)... "What can you say about a sixteen-year-old girl who ... Eight in the Margaret of Greenwich (R) Young Adult ... Books, Inc . These novels narrate the lives of a ... in America. , In this thriller, learning geometry becomes the ... student’s murder plot. Her fears increase when Erika, the only ...
(Date:9/2/2014)... dry eye disease include the sensation of grit in ... disturbance. The causes are poorly understood., The researchers base ... 87 (average age 57) from the TwinsUK cohort, drawn ... London., This cohort is widely regarded as representative of ... look at a wide range of diseases and genetic ...
Breaking Medicine News(10 mins):Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... THURSDAY, March 1 (HealthDay News) -- Where a bird lives ... city dwellers tweeting at a higher pitch than those residing ... recordings, researchers from the University of Copenhagen in Denmark and ... they sing due to city buildings -- not just the ...
... megakaryocytes giant blood cells that produce wound-healing platelets manage ... The findings, to be published March 13 in the journal ... this process may cause a form of leukemia. "A failure ... megakaryoblastic leukemias," said Diane Krause, senior author of the paper, who ...
... THURSDAY, March 1 (HealthDay News) -- Scientists studying mice ... the ability to momentarily retain and utilize information needed ... the March 2 print issue of Cell , ... impairs memory by affecting passive support cells known as ...
... past few decades, doctors have noted a surprising trend ... tongue. Though oral cancer previously appeared predominantly in elderly ... it,s increasing in younger patients: 30- to 50-year-old nonsmokers ... of cancer tends to be less aggressive, and the ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... help people with the rare bone marrow disorder called myelofibrosis. ... the brand name Jakafi, won,t cure myelofibrosis, it can help ... according to the studies. "This is probably the ...
... Aging does not appear to be a factor in poor ... fact, subjective sleep quality seems to improve over a lifetime, with ... flies in the face of popular belief," said Michael Grandner, PhD, ... what we know about sleep in older people men and ...
Cached Medicine News:Health News:City Birds Sing Differently Than Their Country Cousins 2Health News:How red blood cells get so big -- and the bad things that happen when they don't 2Health News:Mayo Clinic: Robotic surgery proves successful, less invasive way to treat HPV-related oral cancer 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Study: Sleep gets better with age, not worse 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: